glp 1 agonist delayed gastric emptying GLP-1 medications safe to continue before surgery in patients with diabetes and obesity GLP-1 Agonists For Obesity In
Description
Thomas, J
In the obesity trial, serious adverse events (SAEs) occurred in 4% of participants with retatrutide use overall (06% across groups) vs
L., Calanna, S., Davies, M., Van Gaal, L
GLP-1 RAs are highlighted as first-line options given their efficacy
Res Commun
A new survey report from the International Foundation of Employee Benefit Plans reveals results from a group of Canadian employers regarding considerations and coverage for glucagon-like peptide-1 (GLP-1) drugs, which have historically been used to treat diabetes and are increasingly being used to treat obesity
